Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

221 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Autologous macrophage therapy for liver cirrhosis: a phase 2 open-label randomized controlled trial.
Brennan PN, MacMillan M, Manship T, Moroni F, Glover A, Troland D, MacPherson I, Graham C, Aird R, Semple SIK, Morris DM, Fraser AR, Pass C, McGowan NWA, Turner ML, Manson L, Lachlan NJ, Dillon JF, Kilpatrick AM, Campbell JDM, Fallowfield JA, Forbes SJ. Brennan PN, et al. Among authors: macpherson i. Nat Med. 2025 Jan 10. doi: 10.1038/s41591-024-03406-8. Online ahead of print. Nat Med. 2025. PMID: 39794616
A trafficking regulatory subnetwork governs αVβ6 integrin-HER2 cross-talk to control breast cancer invasion and drug resistance.
Maldonado H, Dreger M, Bedgood LD, Kyriakou T, Wolanska KI, Rigby ME, Marotta VE, Webster JM, Wang J, Rusilowicz-Jones EV, Marshall JF, Coulson JM, Macpherson IR, Hurlstone A, Morgan MR. Maldonado H, et al. Among authors: macpherson ir. Sci Adv. 2024 Dec 6;10(49):eadk9944. doi: 10.1126/sciadv.adk9944. Epub 2024 Dec 4. Sci Adv. 2024. PMID: 39630893 Free PMC article.
Trastuzumab Duocarmazine in Pretreated Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Breast Cancer: An Open-Label, Randomized, Phase III Trial (TULIP).
Turner N, Saura C, Aftimos P, van den Tweel E, Oesterholt M, Koper N, Colleoni M, Kaczmarek E, Punie K, Song X, Armstrong A, Bianchi G, Stradella A, Ladoire S, Lim JSJ, Quenel-Tueux N, Tan TJ, Escrivá-de-Romaní S, O'Shaughnessy J; TULIP Trial Investigators. Turner N, et al. J Clin Oncol. 2024 Oct 23:JCO2400529. doi: 10.1200/JCO.24.00529. Online ahead of print. J Clin Oncol. 2024. PMID: 39442070
Selection of antibody-binding covalent aptamers.
Soxpollard N, Strauss S, Jungmann R, MacPherson IS. Soxpollard N, et al. Among authors: macpherson is. Commun Chem. 2024 Aug 8;7(1):174. doi: 10.1038/s42004-024-01255-7. Commun Chem. 2024. PMID: 39117896 Free PMC article.
Real world study of sacituzumab govitecan in metastatic triple-negative breast cancer in the United Kingdom.
Hanna D, Merrick S, Ghose A, Devlin MJ, Yang DD, Phillips E, Okines A, Chopra N, Papadimatraki E, Ross K, Macpherson I, Boh ZY, Michie CO, Swampillai A, Gupta S, Robinson T, Germain L, Twelves C, Atkinson C, Konstantis A, Riddle P, Cresti N, Naik JD, Borley A, Guppy A, Schmid P, Phillips M. Hanna D, et al. Among authors: macpherson i. Br J Cancer. 2024 Jun;130(12):1916-1920. doi: 10.1038/s41416-024-02685-9. Epub 2024 Apr 24. Br J Cancer. 2024. PMID: 38658782 Free PMC article.
221 results